Effect of Zinc Supplement on Children with Asthmatic Disease

Effect of Zinc Supplement on the Clinical Symptoms and Spirometry in Children with Moderate Asthmatic Disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105316660N1

Enrollment

300

Registered

2011-07-20

Start date

2010-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthmatic Patients. Asthma

Interventions

Intervention 1: Zinc Sulfte (50 mg/Daily). Intervention 2: Placebo (Suger) for 8 Weeks.

Treatment - Drugs

Placebo

Zinc Sulfte (50 mg/Daily)

Placebo (Suger) for 8 Weeks

Eligibility

Sex/Gender

All

Age

5 Years to 17 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 5-17 years old; asthma more than 1 year; FEV1 <80%. Exclusion criteria: heart, kidney, liver and thyroid diseases; normal spirometry; recent pneumonia and sinusitis; intake of Vitamins or Trace elements.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Clinical manifestation of asthma. Timepoint: 8 weeks. Method of measurement: observation.;Spirometry. Timepoint: 8 Weeks. Method of measurement: Spirometer.	—

Secondary

Measure	Time frame
Eosinophil. Timepoint: 8 weeks. Method of measurement: laboratory test.;Total IgE. Timepoint: 8 Weeks. Method of measurement: Labratory Test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Javad Ghafari

Mazandaran University of Medical Sciences

javadneg@yahoo.com , ghafari@mazums.ac.ir+98 15 1223 3011

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026